By Finance Pulse in RMD —

ResMed Shares Slide on FDA Approval of Eli Lilly's Zepbound

ResMed's stock dips 4% following FDA approval of Eli Lilly's Zepbound, increasing competition in the sleep apnea treatment market.

A sleek, modern image of a stock market screen displaying a downward trend, with a subtle overlay of
ResMed Shares Slide on FDA Approval of Eli Lilly's Zepbound

ResMed shares fell 4% as Zepbound's approval poses competitive pressure on its sleep apnea mask sales.

Source